Surgalign will sell its U.S. hardware and biomaterials assets and equity interests in non-debtor entities related to international hardware business to Xtant Medical for $5 million, according to a company news release. Surgalign also filed a motion looking to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code.
Surgalign’s stock fell 42 percent upon news of its bankruptcy, Seeking Alpha reported June 20. In March, the company announced a 20 percent workforce reduction and sold its Coflex product line to Xtant Medical.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
